Upregulation of FLIPS by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers

被引:106
作者
Nam, SY
Jung, GA
Hur, GC
Chung, HY
Kim, WH
Seol, DW
Lee, BL
机构
[1] Seoul Natl Univ, Coll Med, Dept Anat, Seoul 100799, South Korea
[2] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 100799, South Korea
[3] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 100799, South Korea
[4] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA
[5] Hanyang Univ, Coll Med, Dept Microbiol, Seoul 133791, South Korea
关键词
D O I
10.1111/j.1349-7006.2003.tb01402.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in some, but not all cancer cells. To assess the regulation of TRAIL-resistance in the human gastric cancer cells, we examined TRAIL sensitivity, TRAIL receptor expression, and intracellular signaling events induced by TRAIL. All the gastric cancer cell lines tested were susceptible to TRAIL to some extent, except for SNU-216 cell line, which was completely resistant. TRAIL receptor expression was not related to the TRAIL-sensitivity. Of the cell lines tested, SNU-216 showed the highest level of constitutively active Akt and the short form of FLICE inhibitory protein (FLIPS). Treatment with the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 or with the protein synthesis inhibitor cycloheximide induced a suppression of constitutive Akt activation in SNU-216 cells and a concomitant decrease in the expression of FLIPS. The reduction of Akt activity by LY294002 affected the transcriptional level of FLIPS, but not the mRNA stability. As a result, LY294002 or cycloheximide significantly enhanced TRAIL-induced apoptosis. Moreover, the overexpression of constitutively active Akt in the TRAIL-sensitive cell line, SNU-668, rendered the cell line resistant to TRAIL. In addition, infection of the same cell line with retrovirus expressing FLIPS completely inhibited TRAIL-induced apoptosis by blocking the activation of caspase-8. Therefore, our results suggest that Akt activity promotes human gastric cancer cell survival against TRAIL-induced apoptosis via upregulation of FLIPS, and that the cytotoxic effect of TRAIL can be enhanced by modulating the Akt/FLIPS pathway in human gastric cancers.
引用
收藏
页码:1066 / 1073
页数:8
相关论文
共 39 条
[1]  
Asakuma J, 2003, CANCER RES, V63, P1365
[2]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[3]   The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis [J].
Bin, LH ;
Li, XY ;
Xu, LG ;
Shu, HB .
FEBS LETTERS, 2002, 510 (1-2) :37-40
[4]   TRAIL receptor-2 signals apoptosis through FADD and caspase-8 [J].
Bodmer, JL ;
Holler, N ;
Reynard, S ;
Vinciguerra, P ;
Schneider, P ;
Juo, P ;
Blenis, J ;
Tschopp, J .
NATURE CELL BIOLOGY, 2000, 2 (04) :241-243
[5]  
Burow ME, 1998, CANCER RES, V58, P4940
[6]   Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy [J].
Chinnaiyan, AM ;
Prasad, U ;
Shankar, S ;
Hamstra, DA ;
Shanaiah, M ;
Chenevert, TL ;
Ross, BD ;
Rehemtulla, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) :1754-1759
[7]   Caspases: the executioners of apoptosis [J].
Cohen, GM .
BIOCHEMICAL JOURNAL, 1997, 326 :1-16
[8]   The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain [J].
Degli-Esposti, MA ;
Dougall, WC ;
Smolak, PJ ;
Waugh, JY ;
Smith, CA ;
Goodwin, RG .
IMMUNITY, 1997, 7 (06) :813-820
[9]   HIGH-EFFICIENCY DNA-MEDIATED TRANSFORMATION OF PRIMATE CELLS [J].
GORMAN, C ;
PADMANABHAN, R ;
HOWARD, BH .
SCIENCE, 1983, 221 (4610) :551-553
[10]  
Griffith TS, 1998, J IMMUNOL, V161, P2833